ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zimmer Biomet Holdings, Inc. (ZBH) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators show a neutral to bearish trend, options data reflects bearish sentiment, and the financial performance indicates declining profitability despite revenue growth. Analyst ratings are mixed, with no strong consensus for a buy. Given these factors, holding off on purchasing ZBH at this time is recommended.
The MACD histogram is negative and expanding (-0.709), indicating bearish momentum. RSI is neutral at 32.247, and moving averages are converging, suggesting indecision. The stock is trading below the pivot level of 96.783, with support at 92.745 and resistance at 100.82. This indicates a lack of upward momentum.
Revenue increased by 10.90% YoY in Q4 2025, indicating some top-line growth. Analysts at Citi and TD Cowen have issued buy ratings, citing improving growth and profit stories.
Net income dropped by 41.84% YoY, EPS fell by 41.67%, and gross margin declined by 10.19%, signaling deteriorating profitability. Analyst sentiment is mixed, with several downgrades and reduced price targets. Options data and technical indicators suggest bearish sentiment.
In Q4 2025, revenue grew by 10.90% YoY to $2.24 billion, but net income dropped by 41.84% to $139.3 million. EPS fell by 41.67% to 0.7, and gross margin declined by 10.19% to 56.77%. This reflects a challenging profitability environment despite revenue growth.
Analyst sentiment is mixed. Positive ratings include TD Cowen's upgrade to Buy with a $109 price target and Citi's Buy rating with a $98 price target. Negative ratings include UBS's Sell rating with an $89 price target and Barclays' Underweight rating with a $100 price target. Analysts are concerned about execution issues and inconsistent growth.
